Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007
Open accessThe DOI matches its Crossref record.
Abstract
Purpose: Recent reports have suggested that 40% or more of National Cancer Institute (NCI) –sponsored Cooperative Group phase III trials failed to achieve their accrual goals. We examine in detail the accrual experience of the Cooperative Group phase III trials. Patients and Methods: All Cooperative Group phase III trials activated from 2000 to 2007 were examined for their accrual experience. For trials that stopped accrual with < 90% of their accrual goal, the reasons for having < 90% accrual were documented. We focus on trials that ended with < 90% accrual because of inadequate accrual rates rather than for other reasons, such as an interim monitoring analysis by an independent data monitoring committee that stops the trial early because one treatment is clearly superior. Results: There were 191 trials activated from 2000 to 2007. We project that 22.0% of these trials will have < 90% accrual because of inadequate accrual rates. We project that there will be 176,627 patients eventually accrued on the 191 trials (current accrual, 154,579) and that 2,991of these patients will be on trials that have < 90% accrual because of inadequate accrual rates (1.7%). For nonpediatric cancer trials, the corresponding percentages are 26.7% and 2.0%. Conclusion: We find that insufficient accrual rates are not as high as previously reported and that only a small proportion of patients were enrolled on trials that ended with insufficient accrual because of an inadequate accrual rate. NCI has implemented new procedures to reduce the number of trials that fail to reach their accrual goals and to minimize the number of patients accrued on these trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer
Hamel, L. M., Penner, L. A., Albrecht, T. L., Heath, E., Gwede, C. K., & Eggly, S. (2016) · Cancer Control · doi:10.1177/107327481602300404 · Cited by 463
Carlisle, B., Kimmelman, J., Ramsay, T., & MacKinnon, N. (2015) · Clinical Trials · doi:10.1177/1740774514558307 · Cited by 367
Using a Federated Network of Real-World Data to Optimize Clinical Trials Operations
Topaloglu, U., & Palchuk, M. B. (2018) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00067 · Cited by 349
Adult cancer clinical trials that fail to complete: an epidemic?
Stensland, K. D., McBride, R. B., Latif, A., Wisnivesky, J., Hendricks, R., Roper, N., Boffetta, P., Hall, S. J., Oh, W. K., & Galsky, M. D. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju229 · Cited by 161
Predicting Low Accrual in the National Cancer Institute’s Cooperative Group Clinical Trials
Bennette, C. S., Ramsey, S. D., McDermott, C. L., Carlson, J. J., Basu, A., & Veenstra, D. L. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv324 · Cited by 108
Metadata
- Authors
- Korn, E. L., Freidlin, B., Mooney, M., & Abrams, J. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-12-10
- Volume
- 28
- Issue
- 35
- Pages
- 5197-5201
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165296009
- Cited by
- 60
- References
- 0
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007. https://app.cochat.ai/papers/10.1200/jco.2010.31.5382
- The paper
- Korn, E. L., Freidlin, B., Mooney, M., & Abrams, J. S. (2010). Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.31.5382
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.